BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of Non-Compliance
BIO-key International (NASDAQ: BKYI), a provider of Identity and Access Management solutions, has successfully regained compliance with Nasdaq listing requirements. The company had received a non-compliance notice on April 17, 2025, due to failing to timely file its Annual Report (Form 10-K) for the year ended December 31, 2024, violating Nasdaq Listing Rule 5250(c)(1).
The notification did not immediately affect BKYI's listing status on the Nasdaq Capital Market. The company resolved the issue by filing its Form 10-K on April 23, 2025, and received confirmation of compliance restoration from Nasdaq on April 24, 2025, officially closing the matter.
BIO-key International (NASDAQ: BKYI), fornitore di soluzioni per la Gestione dell'Identità e degli Accessi, ha riconquistato con successo la conformità ai requisiti di quotazione del Nasdaq. L'azienda aveva ricevuto una comunicazione di non conformità il 17 aprile 2025, a causa del mancato deposito tempestivo del suo rapporto annuale (Modulo 10-K) relativo all'anno chiuso il 31 dicembre 2024, violando la Regola di Quotazione Nasdaq 5250(c)(1).
La notifica non ha influenzato immediatamente lo status di quotazione di BKYI sul Nasdaq Capital Market. La società ha risolto il problema depositando il Modulo 10-K il 23 aprile 2025 e ha ricevuto la conferma del ripristino della conformità da Nasdaq il 24 aprile 2025, chiudendo ufficialmente la questione.
BIO-key International (NASDAQ: BKYI), proveedor de soluciones de Gestión de Identidad y Acceso, ha recuperado con éxito el cumplimiento de los requisitos de cotización de Nasdaq. La empresa recibió una notificación de incumplimiento el 17 de abril de 2025, debido a no presentar a tiempo su Informe Anual (Formulario 10-K) correspondiente al año terminado el 31 de diciembre de 2024, incumpliendo la Regla de Cotización Nasdaq 5250(c)(1).
La notificación no afectó inmediatamente el estado de cotización de BKYI en el Nasdaq Capital Market. La compañía solucionó el problema presentando su Formulario 10-K el 23 de abril de 2025 y recibió la confirmación de la restauración del cumplimiento por parte de Nasdaq el 24 de abril de 2025, cerrando oficialmente el asunto.
BIO-key International (NASDAQ: BKYI)는 신원 및 접근 관리 솔루션 제공업체로서 나스닥 상장 요건 준수를 성공적으로 회복했습니다. 회사는 2025년 4월 17일, 2024년 12월 31일 종료된 연례 보고서(Form 10-K)를 기한 내에 제출하지 않아 나스닥 상장 규정 5250(c)(1)을 위반했다는 비준수 통지를 받았습니다.
이 통지는 BKYI의 나스닥 자본시장 상장 상태에 즉시 영향을 미치지 않았습니다. 회사는 2025년 4월 23일 Form 10-K를 제출하여 문제를 해결했고, 2025년 4월 24일 나스닥으로부터 준수 회복 확인을 받아 이 사안을 공식적으로 종료하였습니다.
BIO-key International (NASDAQ : BKYI), fournisseur de solutions de gestion des identités et des accès, a réussi à rétablir sa conformité aux exigences de cotation du Nasdaq. La société avait reçu un avis de non-conformité le 17 avril 2025, en raison du dépôt tardif de son rapport annuel (Formulaire 10-K) pour l'exercice clos le 31 décembre 2024, en violation de la règle de cotation Nasdaq 5250(c)(1).
Cette notification n'a pas immédiatement affecté le statut de cotation de BKYI sur le Nasdaq Capital Market. La société a résolu le problème en déposant son formulaire 10-K le 23 avril 2025 et a reçu la confirmation du rétablissement de sa conformité par le Nasdaq le 24 avril 2025, clôturant officiellement l'affaire.
BIO-key International (NASDAQ: BKYI), ein Anbieter von Identity- und Access-Management-Lösungen, hat die Einhaltung der Nasdaq-Listenanforderungen erfolgreich wiederhergestellt. Das Unternehmen erhielt am 17. April 2025 eine Mitteilung über die Nichteinhaltung, da der Jahresbericht (Formular 10-K) für das am 31. Dezember 2024 endende Jahr nicht fristgerecht eingereicht wurde, was gegen die Nasdaq-Listenregel 5250(c)(1) verstößt.
Die Mitteilung hatte keine unmittelbaren Auswirkungen auf den Notierungsstatus von BKYI am Nasdaq Capital Market. Das Unternehmen löste das Problem durch die Einreichung des Formulars 10-K am 23. April 2025 und erhielt am 24. April 2025 die Bestätigung der Wiederherstellung der Compliance von Nasdaq, womit die Angelegenheit offiziell abgeschlossen wurde.
- Quick resolution of compliance issues (within 6 days)
- Maintained Nasdaq listing status without trading disruption
- Failed to meet SEC filing deadlines for 2024 Annual Report
- Received regulatory non-compliance notice from Nasdaq
HOLMDEL, N.J. , April 24, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced today that on April 17, 2025, it received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2024. The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.
On April 23, 2025, the Company filed its Form 10-K for the year ended December 31, 2024 with the SEC. On April 24, 2025, the Company received notice from Nasdaq stating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) and that the matter has been closed.
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud-hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
Engage with BIO-key
| Corporate | ||
| Facebook: LinkedIn: X: | https://www.facebook.com/BIOkeyInternational/ https://www.linkedin.com/company/bio-key-international @BIOkeyIntl | |
| Investors | ||
| X: StockTwits: | @BIO_keyIR @BIO_keyIR | |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
FAQ
What caused BIO-key (BKYI) to receive a Nasdaq non-compliance notice in April 2025?
How did BIO-key (BKYI) resolve its Nasdaq listing compliance issue?
Was BKYI's stock trading affected by the Nasdaq non-compliance notice?
What is Nasdaq Listing Rule 5250(c)(1) that BKYI violated?
